As a first-time investor, it can be daunting trying to figure out where to put your money. But don’t worry, we’ve got you covered. Join us as we cover different types of investments!

What are the most popular types of investments? | Get Rich Slow Club

Whilst none of us are the next Warren Buffett, we have the ability to "own a piece of America", as he often suggests. For this reason, we're sharing the 10 most most popular US stocks on Pearler. 

Check out Pearler's most popular US stocks

Think of community data as a compass: you can choose any stock you want, but our community keeps pointing in the same general direction - simple, diversified, and cheap ETFs. Let's take a look at the 10 most popular ETFs on Pearler.

These are Pearler's most popular ETFs

Roivant Sciences Ltd. (ROIV:US) Share Price | Pearler

IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

The iShares S&P 500 ETF seeks to track the investment results of an index composed of large-capitalisation U.S. equities.

iShares S&P 500 Etf

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

Vanguard Australian Shares Index ETF (ASX: VAS) seeks to track the performance of the ASX 300 index before account fees, expenses, and taxes. The index tracks the top 300 companies on the Australian Securities Exchange (ASX). These are mostly large and established Australian companies. It is a popular choice among passive individual investors who don't have the time or the expertise to actively invest in stocks.

Vanguard Australian Shares Index Etf

Rockwell Automation, Inc. is a provider of industrial automation and digital transformation. The Company’s segments include Intelligent Devices, Software & Control, and Lifecycle Services. The Intelligent Devices segment includes drives, motion, safety, sensing, industrial components, and configured-to-order products. The Software & Control segment includes control and visualization software and hardware, information software, and network and security infrastructure. The Lifecycle Services segment includes consulting, professional services, and solutions, connected services, and maintenance services, as well as the Sensia joint venture. The Company's products include hardware, software, and configured-to-order products. Its solutions include custom-engineered systems and software. Its services include customer technical support and repair, asset management and optimization consulting, and training. It serves various industries, such as aerospace, cement, chemical, and entertainment.

Rockwell Automation Inc.

Retail Opportunity Investments Corp. (ROIC) is a fully integrated, self-managed real estate investment trust (REIT). The Company is engaged in the acquisition, ownership and management of necessity-based community and neighborhood shopping centers on the west coast of the United States, anchored by supermarkets and drugstores. It operates its business through, its operating partnership subsidiary, Retail Opportunity Investments Partnership, LP. The Company is organized in an umbrella partnership real estate investment trust (UpREIT) format pursuant to which Retail Opportunity Investments GP, LLC, which serves as the general partner. The operating partnership holds all the assets of the Company and directly or indirectly holds the ownership interests in the Company’s real estate ventures. The Company's portfolio consists of approximately 94 properties totaling approximately 10.6 million square feet of gross leasable area (GLA).

Retail Opportunity Investments Corp.

Roivant Sciences Ltd. is a pharma company. The Company is focused on developing transformative medicines that address areas of unmet medical need. The Company, through its subsidiaries, is focused on delivering medicines and technologies to patients. The Company builds biotech and healthcare technology companies (Vants) and deploys technology to drive research and development and commercialization. The Company’s product candidate includes VTAMA (tapinarof), IMVT-1401, Brepocitinib, Namilumab and RVT-2001. Its Vant family includes Dermavant, Immunovant, Priovant, Kinevant and Hemavant. Its small molecule discovery engine is powered by computational physics and machine learning (ML) capabilities for in silico drug design. The Company’s capabilities in diverse therapeutic areas, including immunology, dermatology and oncology, and modalities, including biologics, topicals and bifunctional small molecules.

Roivant Sciences Ltd.

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company's other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.

Gilead Sciences Inc.

Global X Lithium ETF (the Fund) seeks to provide investment results that correspond generally to the price and yield performance of the Solactive Global Lithium Index (the Index). The Index is free float adjusted, liquidity tested and market capitalization-weighted index that is designed to measure broad based equity market performance of global companies involved in the lithium industry, as defined by Structured Solutions AG. The Fund will normally invest at least 80% of its total assets in the securities of the Index and in depositary receipts based on the securities in the Index. The Fund will concentrate its investments (will hold 25% or more of its total assets) in a particular industry or group of industries to approximately the same extent that the Index is concentrated. The Index is sponsored by Structured Solutions AG, the index provider. The Fund’s investment adviser is Global X Management Company LLC.

Global X Lithium & Battery Tech ETF

Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer globally through the use of its proprietary tests, vast data sets and advanced analytics. The Company has developed its Guardant360, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced-stage cancer. It also has developed Guardant360 TissueNext tissue test for advanced-stage cancer, Guardant Reveal blood test to detect residual and recurring disease in early-stage cancer patients, and Guardant360 Response blood test to predict patient response to immunotherapy or targeted therapy eight weeks earlier than current standard-of-care imaging. The Company’s GuardantINFORM platform is used to help biopharmaceutical companies accelerate precision oncology drug development through the use of this in-silico research platform to unlock further insights into tumor evolution and treatment resistance across various biomarker-driven cancers.

Guardant Health, Inc.

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. It develops T-cell therapies for solid tumors and has reported responses in multiple solid tumor indications. Its platform helps to identify cancer targets, find and develop cell therapy candidates active against those targets and produce therapeutic candidates for administration to patients. Its cell therapy candidates include genetically engineered T-cell receptors (TCRs) and HLA-independent TCRs (HiTs) where surface proteins are targeted independently of the peptide-HLA complex. Its MAGE-A4 cell therapy franchise includes T-cell therapy products targeting solid tumor indications in which the MAGE-A4 antigen is expressed, with responses seen in eight indications (head and neck, esophagogastric junction, non-small cell lung cancer-squamous, synovial sarcoma, melanoma, urothelial, ovarian and myxoid/round cell liposarcoma indications).

Adaptimmune Therapeutics plc

Denali Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company’s clinical-stage programs include Antibody Transport Vehicle (ATV): triggering receptors expressed on myeloid cells 2 (TREM2), Protein Transport Vehicle (PTV): progranulin (PGRN), eukaryotic initiation factor 2 B (eIF2B), receptor-interacting serine/threonine protein kinase 1 (RIPK1), Enzyme Transport Vehicle (ETV): iduronate 2-sulfatase (IDS) and leucine-rich repeat kinase 2 (LRRK2), which are in various Phases ranging from Phase I through Phase III. The Company’s product candidates include DNL310, TAK-594/DNL593, TAK-920/DNL919, BIIB122/DNL151, DNL343, SAR443820/DNL788 and SAR443122/DNL758. The Company engineers its product candidates to cross the BBB, and act directly in the brain.

ROIV

Buy

👑 Overview

📈

-1.57%

Annual Growth

🌏

1

Pearlers Invested

Key information

🔎 Fund Overview

Price History*

Unsure how much or often to invest?

🗓️ Investing frequency calculator

💵 Investing amount calculator

⏱️ Investing duration calculator

💵

6.50 AUD*

Purchase Fee

💼

N/A

Management Fee

💸

Want to know the long term costs?

Calculate the historic long term costs to hold your investments

Technical Info

$9.31

How our community is investing

1

N/A

N/A

N/A

1170 days

ROIV investor breakdown

💵 Income of investors

100%

👶 Age of investors

100%

🙋 Legal gender of investors

100%

$77.09 USD

Find Out More

$61.90 USD

Find Out More

$28.08 USD

Find Out More

$1.12 USD

Find Out More

$29.96 USD

Find Out More

$286.23 USD

Find Out More

$12.21 USD

Find Out More

Buy